Everest Medicines names new CCO
18 February 2021 -

Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Thursday that it has named Kevin Guo as its new chief commercial officer.

Guo has over 22 years of commercial leadership and business management experience across various multinational pharmaceutical companies. He has held the position of vice president and deputy global brand lead for LENVIMA, vice president and head of the pharmaceutical business division of Eisai China Inc, chairman of the board and president of Eisai (Suzhou) Trading Co Ltd, vice president of Oncology Business Unit 1 in Shanghai Roche Pharmaceutical Ltd, among other key commercial and business development positions at prominent global pharmaceutical companies, including GlaxoSmithKline plc, Wyeth Pharmaceuticals Co Ltd (now part of Pfizer Inc), Sino-American Shanghai Squibb Pharmaceutical Limited and Eli Lilly Asia Inc.

Guo holds a Bachelor's degree in clinical medicine from Fourth Military University in China and Executive MBA from China Europe International Business School.